During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
The pooled prevalence of GERD in the Indian population is 15.6 %
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
The drug will target specific genetic mutations prevalent in certain types of cancers
Subscribe To Our Newsletter & Stay Updated
